Clinical Trials Logo

Birth Asphyxia clinical trials

View clinical trials related to Birth Asphyxia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05854745 Active, not recruiting - Neonatal Death Clinical Trials

Comparison of Virtual Training to In-Person Training of Helping Babies Breathe in Ethiopia

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Helping Babies Breathe (HBB) is a program that teaches providers in low- and middle-income countries about neonatal resuscitation. Historically, HBB training was delivered in person. During the COVID-19 pandemic, many subject matter experts were unable to travel to conduct HBB courses. Innovative methods for teaching HBB are needed to promote the acquisition and retention of resuscitation skills and knowledge.

NCT ID: NCT05349175 Active, not recruiting - Birth Asphyxia Clinical Trials

Augmented Infant Resuscitator (AIR): Transitioning a Novel Behavior Change Innovation to Drive Newborn Ventilation Skills Enhancement

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Augmented Infant Resuscitator (AIR) is an inexpensive add-on, compatible with nearly every existing bag-valve mask and many types of ventilation equipment. AIR monitors ventilation quality and provides real-time objective feedback and actionable cues to clinicians to both shorten training times and improve resuscitation quality, adoption, retention, and confidence.

NCT ID: NCT04714502 Active, not recruiting - Birth Asphyxia Clinical Trials

Asphyxia Associated Metabolite Biomarker Investigation 2

AAMBI2
Start date: July 2, 2019
Phase:
Study type: Observational

Follow-up of participants of AAMBI1 study at age of at least 2 years. AAMBI1(ClinicalTrials.gov ID: NCT03354208): Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia. These biomarkers linked to asphyxia have been identified in animal studies.

NCT ID: NCT04169191 Active, not recruiting - Birth Asphyxia Clinical Trials

Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia

SANE-02
Start date: September 19, 2019
Phase: Phase 1
Study type: Interventional

The investigators will determine the maximum tolerable dose of sildenafil and establish the pharmacokinetic and pharmacodynamic profile of sildenafil in human asphyxiated neonates treated with hypothermia. They will use a 3+3 design to escalate the sildenafil dose up to 6 mg/kg/day (3mg/kg/dose q12h) in asphyxiated neonates demonstrating brain injury despite hypothermia treatment and assess whether we observe any beneficial effects of sildenafil on their brain and cardiopulmonary hemodynamics, without causing serious adverse events